Synovitis, Pigmented Villonodular clinical trials
The registry lists 20 studies for Synovitis, Pigmented Villonodular across more than 10 countries. 2 are recruiting or about to start. 19 of them are mainly about Synovitis, Pigmented Villonodular (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Synovitis, Pigmented Villonodular studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Daiichi Sankyo (3) · AmMax Bio, Inc. (3) · Deciphera Pharmaceuticals, LLC (2) · Peking University Third Hospital (2) · SynOx Therapeutics Limited (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Andrew J. Wagner, MD, PhD (1) · Centre Leon Berard (1)
What is being tested here
Drugs under test in Synovitis, Pigmented Villonodular studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Pimicotinib | 1 | 1 | 2 |
| Pexidartinib | 0 | 1 | 3 |
| Anti-CSF1R Monoclonal Antibody AMB-05X | 0 | 0 | 3 |
| Vimseltinib | 0 | 1 | 2 |
| Nilotinib | 0 | 0 | 2 |
| Emactuzumab | 0 | 1 | 1 |
| Cabiralizumab | 0 | 0 | 1 |
| Lacnotuzumab | 0 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Synovitis, Pigmented Villonodular studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 20 studies, recruiting or not: 5% stop at 75 or younger and 5% at 65; 15% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular SynovitisRecruitingNCT07503821Not applicable1 country
- Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell TumorNot yet recruitingNCT07707882Phase 21 country
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell TumorCompletedNCT01207492Phase 21 country
- Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)Active, not recruitingNCT05417789Phase 312 countries
- Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruitingNCT03069469Phase 1/29 countries
- A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanCompletedNCT04703322Phase 21 country
- Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Active, not recruitingNCT05804045Phase 37 countries
- Study of Vimseltinib for Tenosynovial Giant Cell TumorActive, not recruitingNCT05059262Phase 313 countries
- A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCTCompletedNCT05349643Phase 23 countries
- An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the KneeCompletedNCT04731675Phase 24 countries
- A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor PatientsTerminatedNCT04938180Phase 23 countries
- Tenosynovial Giant Cell Tumors (TGCT) Observational Platform ProjectCompletedNCT029480888 countries
- Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial DiseaseCompletedNCT049528961 country
- Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedNCT02371369Phase 312 countries
- Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell TumorCompletedNCT02471716Phase 1/26 countries
- Screening of Specific Genes for Pigmented Villous Nodular SynovitisCompletedNCT049555351 country
- Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedNCT03291288Phase 14 countries
- MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)CompletedNCT01643850Phase 22 countries
- A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorTerminatedNCT02673736Phase 11 country
- Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)CompletedNCT01261429Phase 25 countries